Revolution Medicines Presents Encouraging Data for RAS Inhibitor in Pancreatic Cancer
Event summary
- Revolution Medicines presented updated Phase 1/2 clinical data for daraxonrasib, an oral RAS(ON) inhibitor, at the 2026 AACR Annual Meeting.
- Data showed encouraging preliminary antitumor activity in both monotherapy and combination (daraxonrasib plus gemcitabine and nab-paclitaxel) cohorts for first-line metastatic pancreatic ductal adenocarcinoma (PDAC).
- The combination therapy demonstrated a 58% objective response rate (ORR) and 6-month progression-free survival (PFS) of 84%, while monotherapy showed a 47% ORR and 6-month PFS of 71%.
- These findings support continued evaluation of daraxonrasib in the ongoing Phase 3 RASolute 303 trial.
- Revolution Medicines previously announced that the Phase 3 RASolute 302 trial in previously treated patients met all primary and key secondary endpoints.
The big picture
Revolution Medicines' data represents a significant step forward in targeting RAS-addicted cancers, a historically challenging area with high unmet need. Pancreatic cancer, with its low survival rates and resistance to standard therapies, represents a multi-billion dollar market opportunity. The positive signals from both monotherapy and combination data suggest a broader applicability for daraxonrasib, but the Phase 3 trial results will be the ultimate determinant of its commercial viability.
What we're watching
- Clinical Validation
- The success of the Phase 3 RASolute 303 trial will be critical to validating daraxonrasib's efficacy in the first-line setting and driving potential regulatory approval.
- Competitive Landscape
- The emergence of other RAS inhibitors will likely intensify competition and necessitate a differentiated value proposition for daraxonrasib to achieve market share.
- Regulatory Pathway
- The FDA's assessment of the safety and efficacy data, particularly concerning the observed adverse events, will influence the potential approval timeline and label.
Related topics